Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masofaniten with Abiraterone or Apalutamide in mCRPC
NCT05295927Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of masofaniten in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events (AEs), Number of Participants with AEs by Severity and 2 more. Started Mar 2022; status: terminated.
02
Drugs
masofaniten
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05295927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295927.